Lutescu, Ioana; Gussi, Ilinca; Banceanu, G.; CocuIescu, M.
April 2007
Acta Endocrinologica (1841-0987);Apr-Jun2007, Vol. 3 Issue 2, p141
Academic Journal
Introduction. Estrogens are known to have a neuroprotective role and to influence the permeability of the blood brain barrier (BBB). An ongoing debate exists on the changing effects of estrogens on target tissues with advancing age and at menopause and on the potential disruptive role of increasing gonadotropin levels. The aim of the present study was to assess the permeability of the BBB for estradiol, FSH and LH in three physiological states: early follicular phase, preovulatory phase and at menopause. Method. Hormonal levels were assessed simultaneously in the serum and cerebrospinal fluid (CSF) of 15 women at menopause (mean age 60±8 years), 16 of reproductive age in early follicular phase and 11 in preovulatory phase (mean age 31±7 years), all undergoing surgery for benign gynecologic disorders. FSH, LH and estradiol levels were assessed using chemo luminescence and are expressed as median and 10-90 percentile interval. Statistical analysis assessed the serum-CSF correlation and the CSF/serum ratio for each hormone between groups. Results. Estradiol serum levels were 26.2 pg/mI (6.4-43.5) at menopause (n=15), 58.5 pg/mI (25.7-75.9) in early follicular phase (EFP, n=16) and 221.2 pg/mI (113.7-405.5) in preovulatory phase (PREOV, n=11). CSF estradiol is 18.5 pg/ml (0.4-30.5) at menopause, 5.4 pg/mI (2.2-10.2) in EFP (p<0.001) and 17.3 pg/mI (10.3-34.6) in PREOV patients. Estradiol serum and CSF levels correlate positively in the fertile cycle (r=0.72, p<0.0001) and negatively at menopause (r=-0.88, p<0.05). The CSF/serum ratio for estradiol is 0.8 (0.01-4.4) at menopause, 0.1 (0.04-0.13) in EFP and 0.1 (0.03-0.13) in PREOV patients. FSH serum levels were 75.8 mUI/ml (35.9-129.8) at menopause, 7.7 mUI/mI (3.5- 11.4) in EFP and 7.3 mUI/mI (3.1-10.7) in PREOV patients. CSF FSH is 2.7 mUI/ml(0.4-5.9) at menopause, significantly higher than 0.7 mUI/mI (0.3-1) in EFP(p<0.001) and 0.5 mUI/ml (0.2-1) in PREOV patients (p<0.05). FSH serum and CSF levels correlate positively in the fertile cycle (r=0.8, p<0.0001) and do not correlate at menopause (p=NS). The CSF/serum ratio for FSH is 0.03 (0.01-0.1) at menopause, significantly lower than 0.09 (0.06-0.16) in EFP (p<0.001) and is 0.06 (0.03-0.13) in PREOV phase. LH serum levels were 57.4 mUI/ml (27.5-84.8) at menopause, 4.7 mUI/ml (1.7-7.1) in EFP and 5.5 mUI/ml (4.9-8.02) in PREOV phase. CSF LH is 1.6 mUI/ml (0.7-2.6) at menopause, significantly higher than 0.4 mUI/ml (0.1-1) in EFP (p<0.001) and 0.5 mUI/ml (0.2-0.9) in preovulatory phase (p<0.05). The CSF/serum ratio for LH is 0.03 (0.01-0.07) at menopause, it is significantly lower than 0.09 (0.03-0.27) in EFP (p<0.001) and is 0.07 (0.03-0.14) in preovulatory phase. Conclusions. This study shows the negative correlation of serum and CSF estradiol levels at menopause reflecting the need of constant estrogen levels within the CSF despite low chronic serum levels. Simultaneously, the CSF/serum ratio for gonadotrophins is reduced significantly at menopause and the positive correlation of serum and CSF levels is lost, reflecting a protective mechanism against rising levels of FSH and LH.


Related Articles

  • The Aging Ovary. Shifren, Jan L.; Schiff, Isaac // Journal of Women's Health & Gender-Based Medicine;Jan2000 Supplement 1, Vol. 9 Issue 1, p3 

    During reproductive life, ovarian steroid biosynthesis is gonadotropin dependent and occurs in theca and granulosa cells. In the menopausal ovary, there is atresia of ovarian follicles, with sparing of the androgen-producing theca-interstitial cell component. The aging ovary, therefore, produces...

  • Semantic Similarity for Automatic Classification of Chemical Compounds. Ferreira, João D.; Couto, Francisco M. // PLoS Computational Biology;Sep2010, Vol. 6 Issue 9, p1 

    With the increasing amount of data made available in the chemical field, there is a strong need for systems capable of comparing and classifying chemical compounds in an efficient and effective way. The best approaches existing today are based on the structure-activity relationship premise,...

  • Production and Actions of Estrogens. Gruber, Christian J.; Tschugguel, Walter; Schneeberger, Christian; Huber, Johannes C. // New England Journal of Medicine;1/31/2002, Vol. 346 Issue 5, p340 

    The article presents information on the new biochemical and molecular aspects of the action of estrogen and on its clinical and physiologic aspects. The naturally occurring estrogens are steroids derived from cholesterol. Different steroids are formed by reduction of the number of carbon atoms...

  • Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Annemarie G.M.G.J. Mulders; Joop S.E. Laven; Marinus J.C. Eijkemans; Frank H. de Jong; Axel P.N. Themmen; Bart C.J.M. Fauser // Human Reproduction;Sep2004, Vol. 19 Issue 9, p2036 

    BACKGROUND: Anti-Müllerian hormone (AMH), produced by growing pre-antral and early antral ovarian follicles, has been shown to be a useful marker for ovarian ageing. Serum AMH concentrations are elevated during reproductive life in anovulatory women, especially in those patients exhibiting...

  • Influence of estradiol-17β, testosterone, and 11-ketotestosterone on testicular development, serum steroid hormone, and gonadotropin secretion in male red sea bream Pagrus major. Yamaguchi, Sonoko; Gen, Koichiro; Okuzawa, Koichi; Matsuyama, Michiya; Kagawa, Hirohiko // Fisheries Science;Aug2006, Vol. 72 Issue 4, p835 

    In order to investigate the influence of estrogen and androgen on reproductive activities of male teleosts, male red sea bream were implanted with silicone capsules containing estradiol-17β (E2), testosterone (T) or 11-ketotestosterone (11-KT) in immature and early spermatogenic stages. One...

  • Don't let your doctor give you horse urine. MORGENTHALER, JOHN; WRIGHT, JONATHAN V. // Total Health;Dec98/Jan99, Vol. 20 Issue 5, ANTI-AGING NEWSLETTER p8 

    Reports that the `estrogen' replacement most doctors prescribe for menopausal and premenopausal women is a pill known as conjugated equine estrogens (CEE). Premarin, as the best known brand of CEE; Symptoms of menopause; Disadvantages of using CEE; Estrogenic effects produced by Premarin;...

  • Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause. Chakravarti, S.; Collins, W.P.; Thom, M.H.; Studd, J.W.W. // British Medical Journal;4/14/1979, Vol. 1 Issue 6169, p983 

    Examines the relation between plasma hormone profiles, symptoms, and response to estrogen treatment in women approaching the menopause. Complaints of women with vasomotor symptoms; Methods of selecting patients for estrogen-replacement therapy; Symptoms of estrogen deficiency.

  • Estrogen plus progestin increased coronary heart disease and breast cancer events in postmenopausal women. Lowe, Julia // ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p41 

    Presents information on a study that investigated the risks and benefits of estrogen plus progestin in healthy postmenopausal women. Design of the study; Analysis of the incidence of diseases between the placebo-controlled trial versus estrogen plus progestin; Rate of unfavorable and favorable...

  • Menopause: Dreadful Affliction or Glorious Transition? Gursche, Siegfried // Alive: Canada's Natural Health & Wellness Magazine;Jul2003, Issue 249, p82 

    Provides information on menopause. Definition of menopause from biological medicine's point of view; Most commonly prescribed estrogen for hormone replacement therapy; Nutritional supplements as an alternative to HRT.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics